Prospective triAl of Modified Treat-and-extend Regimens With BroLucizumab in pachychOroid Neovasculopathy
Status:
Not yet recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
PNV is a recently described clinical entity; therefore, studies about treatment efficacy and
safety are few, with limited follow-up and a small number of participants. Treatment is based
on intravitreal anti-VEGF injections, similar to neovascular AMD. According to reported
results however, efficacy seems different in fluid reabsorption among anti-VEGF agents. A
newly developed anti-VEGF molecule for the treatment of neovascular AMD, brolucizumab, has
been shown in clinical studies to have longer durability and improved visual outcomes using a
q12-week regimen, thus having the potential to reduce treatment burden and serve as an
important therapeutic tool in the management of neovascular AMD. Nevertheless, there have
been no reports specifically focusing on the efficacy of brolucizumab in the treatment of
PNV. The purpose of this study is to evaluate the efficacy and safety profile of the modified
treat-and-extend regimen to 64 weeks by intravitreal brolucizumab injection in eyes with
treatment-naive pachychoroid neovasculopathy (PNV) patients.